Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Melisi, Davide
Quinzii, Alberto
Valente, Monica
Di Giacomo, Anna Maria
Amato, Giovanni
Simonetti, Elena
Zecchetto, Camilla
Casallino, Simona
Leta, Luigi
Messineo, Luisa
Mendo, Lucia
Hammett, Tracey
Deken, Marcel
Di Conza, Giusy
Kaur, Paramjit
Lahn, Michael M. F.
Maio, Michele
机构：
[1] Univ Verona, Verona, Italy
[2] Azienda Osped Univ Integrata, Verona, Italy
[3] Azienda Osped Univ Integrata, Invest Canc Therapeut Clin Unit, Verona, Italy
[4] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[5] Univ Siena, Siena, Italy
[6] Azienda Osped Univ Senese, UOC Immunoterapia Oncol, Siena, Italy
[7] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy
[8] AOUI Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[9] Univ Verona, Scuola Specializzaz Oncol Med, Verona, Italy
[10] iOnctura SA, Geneva, Switzerland
[11] iOnctura BV, Amsterdam, Netherlands
[12] iOnctura, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15130
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Kimmie Ng
    Andrew Hendifar
    Alexander Starodub
    Jorge Chaves
    Yingsi Yang
    Brian Koh
    David Barbie
    William C. Hahn
    Charles S. Fuchs
    Investigational New Drugs, 2019, 37 : 159 - 165
  • [22] Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study
    Catalano, Martina
    Roviello, Giandomenico
    Conca, Raffaele
    D'Angelo, Alberto
    Palmieri, Valeria Emma
    Panella, Benedetta
    Petrioli, Roberto
    Ianza, Anna
    Nobili, Stefania
    Mini, Enrico
    Ramello, Monica
    CURRENT CANCER DRUG TARGETS, 2020, 20 (11) : 887 - 895
  • [23] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
  • [24] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Ruihua Xu
    Xianjun Yu
    Jihui Hao
    Liwei Wang
    Hongming Pan
    Guohong Han
    Jianming Xu
    Yanqiao Zhang
    Shujun Yang
    Jia Chen
    Jieer Ying
    Guanghai Dai
    Mingyu Li
    Damir Begic
    Brian Lu
    Lin Shen
    BMC Cancer, 17
  • [25] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Xu, Ruihua
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jianming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian
    Shen, Lin
    BMC CANCER, 2017, 17
  • [26] Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer
    Aoki, Yu
    Sukawa, Yasutaka
    Kawasaki, Kenta
    Suzuki, Takeshi
    Hirata, Kenro
    Kasuga, Akiyoshi
    Iwasaki, Eisuke
    Hamamoto, Yasuo
    Takaishi, Hiromasa
    Kanai, Takanori
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
    Chae, Heejung
    Jeong, Hyehyun
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Kang, Myoung Joo
    Jeong, Jae Ho
    Ryoo, Baek-Yeol
    Kim, Kyu-pyo
    Yoo, Changhoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [28] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [29] Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel plus gemcitabine in metastatic pancreatic ductal adenocarcinoma
    Baron, Kelsey
    Nevala-Plagemann, Christopher Duane
    Moser, Justin
    Haaland, Benjamin
    Wang, Xuechen
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
    Baron, Margaret Kelsey
    Wang, Xuechen
    Nevala-Plagemann, Christopher
    Moser, Justin C.
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    PANCREAS, 2021, 50 (06) : 796 - 802
12345